Evidence map›Paper›PMID 29492793›Full record

ArticleInternational journal of clinical oncology2018

Risk of second malignancies among survivors of pediatric thyroid cancer.

Marwan H Adly, Mohamed Sobhy, Mohamed A Rezk, Medhat Ishak, Mahmoud A Afifi, Ayman El Shafie, Mahmoud Ahmed Ali, Wael Zekri, Ahmad Samir Alfaar, Wafaa M Rashed

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Marwan H AdlyResearch Department-Children's Cancer Hospital Egypt (CCHE-57357), 1 Seket Al-Emam Street, El-Madbah El-Kadeem Yard, El-Saida Zeinab, Cairo, Egypt.
Mohamed SobhyArmed Forces College of Medicine, Ehsan Abd El Kodous Street (From Al Khalifa Al Mamon Street), Cairo, Egypt.
Mohamed A RezkArmed Forces College of Medicine, Ehsan Abd El Kodous Street (From Al Khalifa Al Mamon Street), Cairo, Egypt.
Medhat IshakArmed Forces College of Medicine, Ehsan Abd El Kodous Street (From Al Khalifa Al Mamon Street), Cairo, Egypt.
Mahmoud A AfifiResearch Department-Children's Cancer Hospital Egypt (CCHE-57357), 1 Seket Al-Emam Street, El-Madbah El-Kadeem Yard, El-Saida Zeinab, Cairo, Egypt.
Ayman El ShafieArmed Forces College of Medicine, Ehsan Abd El Kodous Street (From Al Khalifa Al Mamon Street), Cairo, Egypt.
Mahmoud Ahmed AliArmed Forces College of Medicine, Ehsan Abd El Kodous Street (From Al Khalifa Al Mamon Street), Cairo, Egypt.
Wael ZekriPediatric Oncology Department-Children's Cancer Hospital Egypt (CCHE-57357) and Pediatric Oncology Department-National Cancer Institute-Cairo University, 1 Seket Al-Emam Street, El-Madbah El-Kadeem Yard, El-Saida Zeinab, Cairo, Egypt.
Ahmad Samir AlfaarCharité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Mittelallee 4, Office: 0030 0.1952, Augustenburger Platz, 113353, Berlin, Germany.
Wafaa M RashedResearch Department-Children's Cancer Hospital Egypt (CCHE-57357), 1 Seket Al-Emam Street, El-Madbah El-Kadeem Yard, El-Saida Zeinab, Cairo, Egypt. wafaaanor@gmail.com.ORCID http://orcid.org/0000-0001-7531-2840
Armed Forces College of Medicine · EGChildren Cancer Hospital · EGCairo University · EGCharité - Universitätsmedizin Berlin · DE

Funding

ASA is supported by grant 57147166 from The German Academic Exchange Service (DAAD). 57147166
6 · The paper itself

Abstract

backgroundThyroid carcinoma is a very rare tumor in the pediatric age group, accounting for only 1.5-3% of childhood carcinomas in the United States and Europe. We aimed to identify the risk of a second malignancy among pediatric thyroid cancer survivors.

methodsThe cohort analysis consisted of pediatric cancer patients aged less than 20 years, diagnosed with a primary thyroid cancer, identified by site code ICD-0-3: C739, and reported to the SEER 9 database between 1973 and 2013. They were followed up until December 31, 2013; the end of the study period, or up to death if earlier.

resultsOut of 1769 patients diagnosed primarily with thyroid carcinoma, 42 patients had a total of 45 incidences of subsequent malignancies. The mean age of patients at the initial diagnosis of thyroid cancer was 16 years. Females (90.5%) had a significantly higher incidence of second malignancies (SM) than males (9.5%). The overall Standardized Incidence Ratio (SIR) of SM in the study patients was higher than expected (SIR = 1.48). Some specific sites showed significantly higher incidences: the salivary glands (SIR = 33.95), the gum and other parts of the mouth [excluding the lips, tongue, salivary glands and floor of the mouth] (SIR = 24.53)*** and the kidneys (SIR = 5.72). The overall risk of SM in patients who had received radioactive iodine was higher than expected (SIR = 4.41). The cumulative incidence of SM after treatment of thyroid cancer in children increases steadily over 40 years (11.92%).

conclusionsRace, gender, histological subtypes, and radioactive iodine are potentially significant prognostic factors for the development of SM among pediatric thyroid cancer survivors. Identification of underlying mechanisms that raise the risk of SM is important for both treatment and follow-up strategies.

Indexed as

RadiotherapyAdenocarcinoma, FollicularAdenocarcinoma, PapillaryAdolescentAdultCarcinoma, MedullaryChildChild, PreschoolCohort StudiesFemaleHumansIncidenceInfantMaleNeoplasms, Second PrimaryPrognosisPediatric thyroid cancer survivorsSecond malignancySEER

Identifiers

PMID29492793
OpenAlexW2788816018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.